Olema Pharmaceuticals (OLMA) Citigroup’s Biopharma Back to School Summit 2026 summary

Pipeline overview and clinical trial updates

• Lead asset palazestrant is in phase III trials for ER-positive, HER2-negative breast cancer, with OPERA-01 (second/third-line monotherapy) fully enrolled and top-line data expected in Q1 2027.

• OPERA-01 tests both ESR1 mutant and wild-type populations, aiming to show improved progression-free survival (PFS) over standard of care; phase II data showed median PFS of 7 months (mutant) and 5.5 months (wild-type).

• OPERA-02, a first-line trial combining palazestrant with KISQALI, is enrolling well; timeline for readout is not yet communicated due to potential trial adjustments based on emerging control arm data.

• Both trials are powered to detect benefits in distinct patient subsets, with statistical design allowing for positive outcomes in either or both populations.

• Commercial opportunity for palazestrant is estimated at $5 billion (second/third-line) and over $10 billion (first-line) globally, with the U.S. representing the majority of revenue.

Market strategy and commercialization plans

• U.S. launch for second/third-line indication will be self-promoted, requiring fewer than 100 field sales staff; commercial build-out has already begun.

• Outside the U.S., regulatory filings will proceed, but a commercial partner will be sought, likely after phase III data is available.

• Market research and hiring are underway to support a rapid ramp-up post-data readout, with a focus on maximizing U.S. market share.

Competitive landscape and differentiation

• Palazestrant aims to differentiate by exceeding the two-month PFS improvement seen with competitors in the mutant setting and by achieving benefit in the wild-type population, where no agent has succeeded.

• Phase II data for palazestrant included less favorable patient characteristics than OPERA-01, suggesting potential for even better outcomes in the phase III trial.

• Control arm performance in first-line trials is improving over time, prompting possible adjustments in trial powering and patient enrollment criteria.